ヤヌスキナーゼ（JAK）阻害剤の世界市場2019-2023...市場調査レポートについてご紹介

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

2.1 Preface

2.2 Preface

2.3 Currency conversion rates for US$

PART 03: MARKET LANDSCAPE

Market ecosystem

Market characteristics

Market segmentation analysis

PART 04: MARKET SIZING

Market definition

Market sizing 2018

Market size and forecast 2018-2023

PART 05: FIVE FORCES ANALYSIS

Bargaining power of buyers

Bargaining power of suppliers

Threat of new entrants

Threat of substitutes

Threat of rivalry

Market condition

PART 06: MARKET SEGMENTATION BY APPLICATION

Market segmentation by application

Comparison by application

Autoimmune disorders – Market size and forecast 2018-2023

Oncology – Market size and forecast 2018-2023

Market opportunity by application

PART 07: CUSTOMER LANDSCAPE

PART 08: GEOGRAPHIC LANDSCAPE

Geographic segmentation

Geographic comparison

North America – Market size and forecast 2018-2023

Europe – Market size and forecast 2018-2023

Asia – Market size and forecast 2018-2023

ROW – Market size and forecast 2018-2023

Key leading countries

Market opportunity

PART 09: DECISION FRAMEWORK

PART 10: DRIVERS AND CHALLENGES

Market drivers

Market challenges

PART 11: MARKET TRENDS

Increasing research grants

Special drug designations

Rising number of strategic alliances

PART 12: VENDOR LANDSCAPE

Overview

Landscape disruption

Competitive scenario

PART 13: VENDOR ANALYSIS

Vendors covered

Vendor classification

Market positioning of vendors

Astellas Pharma Inc.

Eli Lilly and Co.

Incyte Corp.

Novartis AG

Pfizer Inc.

PART 14: APPENDIX

Research methodology

List of abbreviations

Definition of market positioning of vendors

PART 15: EXPLORE TECHNAVIO

Exhibit 01: Product overview

Exhibit 02: Global pharmaceuticals market

Exhibit 03: Segments of global pharmaceuticals market

Exhibit 04: Market characteristics

Exhibit 05: Market segments

Exhibit 06: Market definition – Inclusions and exclusions checklist

Exhibit 07: Market size 2018

Exhibit 08: Global market: Size and forecast 2018-2023 ($ millions)

Exhibit 09: Global market: Year-over-year growth 2019-2023 (%)

Exhibit 10: Five forces analysis 2018

Exhibit 11: Five forces analysis 2023

Exhibit 12: Bargaining power of buyers

Exhibit 13: Bargaining power of suppliers

Exhibit 14: Threat of new entrants

Exhibit 15: Threat of substitutes

Exhibit 16: Threat of rivalry

Exhibit 17: Market condition – Five forces 2018

Exhibit 18: Application – Market share 2018-2023 (%)

Exhibit 19: Comparison by application

Exhibit 20: Autoimmune disorders – Market size and forecast 2018-2023 ($ millions)

Exhibit 21: Pipeline of JAK inhibitors for autoimmune disorders

Exhibit 22: Autoimmune disorders – Year-over-year growth 2019-2023 (%)

Exhibit 23: Oncology – Market size and forecast 2018-2023 ($ millions)

Exhibit 24: Pipeline of JAK inhibitors for oncology

Exhibit 25: Oncology – Year-over-year growth 2019-2023 (%)

Exhibit 26: Market opportunity by application

Exhibit 27: Customer landscape

Exhibit 28: Market share by geography 2018-2023 (%)

Exhibit 29: Geographic comparison

Exhibit 30: North America – Market size and forecast 2018-2023 ($ millions)

Exhibit 31: North America – Year-over-year growth 2019-2023 (%)

Exhibit 32: Top 3 countries in North America

Exhibit 33: Europe – Market size and forecast 2018-2023 ($ millions)

Exhibit 34: Europe – Year-over-year growth 2019-2023 (%)

Exhibit 35: Top 3 countries in Europe

Exhibit 36: Asia – Market size and forecast 2018-2023 ($ millions)

Exhibit 37: Asia – Year-over-year growth 2019-2023 (%)

Exhibit 38: Top 3 countries in Asia

Exhibit 39: ROW – Market size and forecast 2018-2023 ($ millions)

Exhibit 40: ROW – Year-over-year growth 2019-2023 (%)

Exhibit 41: Top 3 countries in ROW

Exhibit 42: Key leading countries

Exhibit 43: Market opportunity

Exhibit 44: Impact of drivers and challenges

Exhibit 45: Vendor landscape

Exhibit 46: Landscape disruption

Exhibit 47: Vendors covered

Exhibit 48: Vendor classification

Exhibit 49: Market positioning of vendors

Exhibit 50: Astellas Pharma Inc. – Vendor overview

Exhibit 51: Astellas Pharma Inc. – Business segments

Exhibit 52: Astellas Pharma Inc. – Organizational developments

Exhibit 53: Astellas Pharma Inc. – Geographic focus

Exhibit 54: Astellas Pharma Inc. – Key offerings

Exhibit 55: Astellas Pharma Inc. – Key customers

Exhibit 56: Eli Lilly and Co. – Vendor overview

Exhibit 57: Eli Lilly and Co. – Business segments

Exhibit 58: Eli Lilly and Co. – Organizational developments

Exhibit 59: Eli Lilly and Co. – Geographic focus

Exhibit 60: Eli Lilly and Co. – Segment focus

Exhibit 61: Eli Lilly and Co. – Key offerings

Exhibit 62: Eli Lilly and Co. – Key customers

Exhibit 63: Incyte Corp. – Vendor overview

Exhibit 64: Incyte Corp. – Business segments

Exhibit 65: Incyte Corp. – Organizational developments

Exhibit 66: Incyte Corp. – Geographic focus

Exhibit 67: Incyte Corp. – Key offerings

Exhibit 68: Incyte Corp. – Key customers

Exhibit 69: Novartis AG – Vendor overview

Exhibit 70: Novartis AG – Business segments

Exhibit 71: Novartis AG – Organizational developments

Exhibit 72: Novartis AG – Geographic focus

Exhibit 73: Novartis AG – Segment focus

Exhibit 74: Novartis AG – Key offerings

Exhibit 75: Novartis AG – Key customers

Exhibit 76: Pfizer Inc. – Vendor overview

Exhibit 77: Pfizer Inc. – Business segments

Exhibit 78: Pfizer Inc. – Organizational developments

Exhibit 79: Pfizer Inc. – Geographic focus

Exhibit 80: Pfizer Inc. – Segment focus

Exhibit 81: Pfizer Inc. – Key offerings

Exhibit 82: Pfizer Inc. – Key customers

Exhibit 83: Validation techniques employed for market sizing

Exhibit 84: Definition of market positioning of vendors